Skip to main content

Table 2 Baseline characteristics of 24 patients included in the study.

From: Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study

Data, mean (SD) r-hGH
(n = 12)
Control
(n = 12)
p value
t student test
Demographics    
   Age, years 47,4 (7,6) 49,6 (9,4) 0.555
   Weight, kg 72,9 (12,3) 66,0 (9,4) 0.153
   Waist, cm 89.2 (10.3) 76.6 (3.2) 0.01
   BMI, Kg/m2 25,1 (5,3) 162,2 (5,9) 0.334
Fibromyalgia symptoms duration (prior study), months 21 (6) 23 (7) 0,204
Vital signs    
   Systolic blood pressure, mm Hg 124,8 (15,4) 117,5 (10,3) 0.222
   Diastolic blood pressure, mm Hg 80,8 (6,6) 74,2 (7,9) 0.052
   Heart rate, beats/min 75,8 (6,4) 77,9 (11,8) 0.721
Laboratory data    
   GH, ng/mL 0,4 (0,3) 0,9 (0,8) 0.134
   IGF-1 g/L 173.3 (49.4) 98.6 (36.0) <0.001
   TSH, μU/mL 1.3 (0.9) 1.3 (0.9) 0.998
   free T4, ng/mL 3.3 (4.9) 5.5 (6.9) 0.433
   free T3, pg/mL 3.7 (0.7) 2.9 (0.5) 0.041
   Estradiol E2, pg/mL 117.8 (17.7) 98.4 (81.7) 0.708
   P4, ng/mL 0.4 (0.3) 0.7 (0.3) 0.287
   Urinary free cortisol, μg/24 h 98.2 (66.1) 44.5 (11.9) 0.030
   Insulinemia U/dL 11.9 (14.7) 6.0 (2.7) 0.306
   Apolipoprotein B, mg/L 102.8 (26.7) 98.7 (66.1) 0.744
   C-Reactive protein, mg/L 3.2 (0.4) 3.5 (0.0) 0.417
   Erythrocyte sedimentation rate, mm 12.8 (5.8) 11.0 (4.6) 0.482